IL96711A - Insulin-like growth factor for the treatment of adverse effects of steroid laxity - Google Patents

Insulin-like growth factor for the treatment of adverse effects of steroid laxity

Info

Publication number: IL96711A
Authority: IL; Israel
Prior art keywords: igf; analog; active fragment; corticosteroid; pharmaceutical composition
Prior art date: 1989-12-22

Application number

IL9671190A

Other languages

English (en)

Hebrew (he)

Other versions

IL96711A0 (en

Original Assignee

Ciba Geigy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-22

Filing date

1990-12-18

Publication date

1996-01-19

1990-12-18 Application filed by Ciba Geigy filed Critical Ciba Geigy

1991-09-16 Publication of IL96711A0 publication Critical patent/IL96711A0/xx

1996-01-19 Publication of IL96711A publication Critical patent/IL96711A/en

Links

230000000694 effects Effects 0.000 title claims abstract description 82
108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 72
150000003431 steroids Chemical class 0.000 title claims abstract description 64
230000002411 adverse Effects 0.000 title claims abstract description 26
238000002560 therapeutic procedure Methods 0.000 title description 16
102000013275 Somatomedins Human genes 0.000 title description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 70
239000000203 mixture Substances 0.000 claims abstract description 20
239000003246 corticosteroid Substances 0.000 claims description 62
239000012634 fragment Substances 0.000 claims description 36
241000124008 Mammalia Species 0.000 claims description 13
238000009472 formulation Methods 0.000 claims description 12
238000012261 overproduction Methods 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
230000001684 chronic effect Effects 0.000 claims description 5
229960003957 dexamethasone Drugs 0.000 claims description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
241000894007 species Species 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 3
229960005294 triamcinolone Drugs 0.000 claims description 3
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 3
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims description 2
MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims description 2
229940092705 beclomethasone Drugs 0.000 claims description 2
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
229960002537 betamethasone Drugs 0.000 claims description 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
229960004544 cortisone Drugs 0.000 claims description 2
ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 claims description 2
229960003654 desoxycortone Drugs 0.000 claims description 2
229960002011 fludrocortisone Drugs 0.000 claims description 2
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims description 2
229960000618 fluprednisolone Drugs 0.000 claims description 2
229960000890 hydrocortisone Drugs 0.000 claims description 2
229960001810 meprednisone Drugs 0.000 claims description 2
PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 2
229960004584 methylprednisolone Drugs 0.000 claims description 2
229960002858 paramethasone Drugs 0.000 claims description 2
229960005205 prednisolone Drugs 0.000 claims description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
229960004618 prednisone Drugs 0.000 claims description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 22
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
238000010188 recombinant method Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 8
210000000845 cartilage Anatomy 0.000 abstract description 4
230000037314 wound repair Effects 0.000 abstract description 4
230000002401 inhibitory effect Effects 0.000 abstract description 2
239000003708 ampul Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000008121 dextrose Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000008223 sterile water Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
239000000924 antiasthmatic agent Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
239000013066 combination product Substances 0.000 description 2
229940127555 combination product Drugs 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Immunology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

IL9671190A 1989-12-22 1990-12-18 Insulin-like growth factor for the treatment of adverse effects of steroid laxity IL96711A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45521589A	1989-12-22	1989-12-22

Publications (2)

Publication Number	Publication Date
IL96711A0 IL96711A0 (en)	1991-09-16
IL96711A true IL96711A (en)	1996-01-19

Family

ID=23807878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9671190A IL96711A (en)	1989-12-22	1990-12-18	Insulin-like growth factor for the treatment of adverse effects of steroid laxity

Country Status (14)

Country	Link
EP (1)	EP0434625B1 (de)
JP (1)	JP2934023B2 (de)
KR (1)	KR100191381B1 (de)
AT (1)	ATE121296T1 (de)
AU (1)	AU641966B2 (de)
CA (1)	CA2032859C (de)
DE (1)	DE69018799T2 (de)
DK (1)	DK0434625T3 (de)
ES (1)	ES2071080T3 (de)
GR (1)	GR3015900T3 (de)
IE (1)	IE67510B1 (de)
IL (1)	IL96711A (de)
NZ (1)	NZ236614A (de)
ZA (1)	ZA9010332B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5128320A (en) *	1990-01-18	1992-07-07	Genentech, Inc.	Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (de)	1992-03-13	1996-01-01	Ciba Geigy
US5407913A (en) *	1992-12-03	1995-04-18	Celtrix Pharmaceuticals, Inc.	Method and composition for systemic treatment of tissue injury
JPH10504971A (ja) *	1994-09-08	1998-05-19	カイロンコーポレイション	インスリン様増殖因子の改善された生産方法
US5712249A (en) *	1994-09-08	1998-01-27	Ciba-Geigy Corporation	Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU7271996A (en) *	1995-10-23	1997-05-15	Queen's University At Kingston	Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
CA2265972A1 (en) *	1996-09-16	1998-03-26	Philip D. Acott	Use of igf-i for the treatment of polycystic kidney disease and related indications
US6015786A (en)	1997-02-25	2000-01-18	Celtrix Pharmaceuticals, Inc.	Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) *	1997-02-25	2000-02-15	Celtrix Pharmaceuticals, Inc.	Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en)	1997-02-25	2003-02-04	Celtrix Pharmaceuticals, Inc.	Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
AU3548999A (en)	1998-04-03	1999-10-25	Chiron Corporation	Use of igfi for treating articular cartilage disorders
PT1141014E (pt)	1999-01-06	2005-04-29	Genentech Inc	Variante mutante do factor de crescimento semelhante a insulina (igf-i)
WO2001087323A2 (en)	2000-05-16	2001-11-22	Genentech, Inc.	Method for treating cartilage disorders
EP1917039A4 (de)	2005-08-01	2011-01-19	Genera Istrazivanja D O O	Verfahren und zusammensetzungen zur regeneration von gelenkknorpel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE60517B1 (en) *	1986-11-14	1994-07-27	Inst Molecular Biology Inc	Wound healing and bone regeneration
SE8703625D0 (sv) *	1987-09-18	1987-09-18	Kabivitrum Ab	New medical use
US4983581A (en) *	1988-05-20	1991-01-08	Institute Of Molecular Biology, Inc.	Wound healing composition of IGF-I and TGF-β

1990
- 1990-12-12 ZA ZA9010332A patent/ZA9010332B/xx unknown
- 1990-12-13 EP EP90810987A patent/EP0434625B1/de not_active Expired - Lifetime
- 1990-12-13 ES ES90810987T patent/ES2071080T3/es not_active Expired - Lifetime
- 1990-12-13 DK DK90810987.9T patent/DK0434625T3/da active
- 1990-12-13 DE DE69018799T patent/DE69018799T2/de not_active Expired - Fee Related
- 1990-12-13 AT AT90810987T patent/ATE121296T1/de not_active IP Right Cessation
- 1990-12-18 IL IL9671190A patent/IL96711A/en not_active IP Right Cessation
- 1990-12-19 AU AU68247/90A patent/AU641966B2/en not_active Ceased
- 1990-12-20 CA CA002032859A patent/CA2032859C/en not_active Expired - Fee Related
- 1990-12-20 KR KR1019900021111A patent/KR100191381B1/ko not_active Expired - Fee Related
- 1990-12-21 NZ NZ236614A patent/NZ236614A/xx unknown
- 1990-12-21 IE IE468490A patent/IE67510B1/en not_active IP Right Cessation
- 1990-12-21 JP JP2405132A patent/JP2934023B2/ja not_active Expired - Fee Related
1995
- 1995-04-20 GR GR950400745T patent/GR3015900T3/el unknown

Also Published As

Publication number	Publication date
IE67510B1 (en)	1996-04-03
AU6824790A (en)	1991-06-27
AU641966B2 (en)	1993-10-07
CA2032859C (en)	2007-09-17
JPH04210648A (ja)	1992-07-31
ZA9010332B (en)	1991-08-28
EP0434625A3 (en)	1991-10-02
IL96711A0 (en)	1991-09-16
EP0434625A2 (de)	1991-06-26
GR3015900T3 (en)	1995-07-31
CA2032859A1 (en)	1991-06-23
IE904684A1 (en)	1991-07-17
KR100191381B1 (ko)	1999-06-15
KR910011279A (ko)	1991-08-07
NZ236614A (en)	1993-10-26
JP2934023B2 (ja)	1999-08-16
DE69018799D1 (de)	1995-05-24
ATE121296T1 (de)	1995-05-15
ES2071080T3 (es)	1995-06-16
DE69018799T2 (de)	1995-09-21
DK0434625T3 (da)	1995-06-26
EP0434625B1 (de)	1995-04-19

Legal Events

Date	Code	Title
1996-06-18	FF	Patent granted
1997-03-18	KB	Patent renewed
2001-04-30	KB	Patent renewed
2005-02-20	KB	Patent renewed
2010-04-08	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5428011A (en)	1995-06-27	Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
EP0434625B1 (de)	1995-04-19	IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie
AU645874B2 (en)	1994-01-27	Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH)
WO2014179756A1 (en)	2014-11-06	Bone-selective osteogenic oxysterol-bone targeting agents
WO1996024370A1 (en)	1996-08-15	Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
US4916117A (en)	1990-04-10	Treatment of inflammation using alpha 1-antichymotrypsin
AU666514B2 (en)	1996-02-15	Method and composition for the treatment of osteoporosis
US20080090757A1 (en)	2008-04-17	Kahalalide Compositions for the Treatment of Psoriasis
US20110027884A1 (en)	2011-02-03	Combination of insulin and ascorbate to enhance wound healing
JPH08503968A (ja)	1996-04-30	増殖因子と代謝拮抗物質を含有する組成物
JPS6360940A (ja)	1988-03-17	白内障の予防または治療剤
US6596703B1 (en)	2003-07-22	Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
JPH10279500A (ja)	1998-10-20	肥満症治療剤
CA2374933C (en)	2010-10-12	Grf-containing lyophilized pharmaceutical compositions
WO1994005320A1 (en)	1994-03-17	Wound remedy
JPH07118165A (ja)	1995-05-09	カルシトニン遺伝子関連ペプチド類を含有する経皮吸収組成物
KR100834735B1 (ko)	2008-06-09	부신피질 기능 부전증 치료용 부신피질 자극 호르몬의비강 분무 제형
CN121714715A (zh)	2026-03-24	一种溶脂组合物及其应用
JP2688733B2 (ja)	1997-12-10	消化管粘膜障害の予防及び治療剤
JPH06179628A (ja)	1994-06-28	創傷治癒促進剤